Does roflumilast induce phagocytic activity in COPD patients?
نویسندگان
چکیده
منابع مشابه
Does roflumilast induce phagocytic activity in COPD patients?
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be f...
متن کاملRoflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
BACKGROUND A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently, roflumilast has been added as a therapeutic option for COPD. Roflumilast is an oral phosphodiesterase-4 inhibitor that targets inflammatory cells involved in triggering exacerbations of COPD. The objective of the current study was to evalua...
متن کاملRoflumilast in COPD.
We read with interest the Point and Counterpoint editorials in CHEST (May 2014) by Suissa and Rabe 1 and Rho et al 2 about the appropriateness of industry-sponsored rofl umilast trials. In the editorials, reference was made to the level of patient withdrawal as well as to the level of side eff ects experienced by patients receiving this drug during clinical trials. 2 In our real-world clinical ...
متن کاملEfficacy and Safety of Roflumilast in Korean Patients with COPD
PURPOSE Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV₁) <50% predicted] with chronic bronchitis and a history of frequent exacerbations. This study evaluated the efficacy and safety of roflumilast in Korean patients with COPD and compared the effica...
متن کاملVulnerable COPD patients with comorbidities: the role of roflumilast
Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in February 2011 for the management of chronic obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the terms "roflumilast" and "COPD". Reference citations from publications identified were also reviewed. All articles published in English using...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Chronic Obstructive Pulmonary Disease
سال: 2015
ISSN: 1178-2005
DOI: 10.2147/copd.s92812